Biopharmaceutical Contract Manufacturing Industry’s 10.5% CAGR Towards US$18.7 Billion in 2029 | FMI

The Global Biopharmaceutical Contract Manufacturing Industry, valued at approximately US$ 9.3 billion in 2022, is set to experience robust growth at a Compound Annual Growth Rate (CAGR) of 10.5%. It is expected to reach a staggering US$ 18.7 billion by 2029. This meteoric rise reflects the growing trend among pharmaceutical companies to outsource their biopharmaceutical manufacturing operations.

The biopharmaceutical contract manufacturing sector offers a myriad of advantages, including access to cutting-edge technologies, expedited time-to-market for new pharmaceuticals, and enhanced flexibility. These compelling benefits have prompted several multinational corporations to leverage the expertise of contract manufacturing firms.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-2982

Regional Insights:

The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period.

Germany is set to exhibit a CAGR of over 11.5% in the European Biopharmaceutical Contract Manufacturing Industry during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option.

China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the Biopharmaceutical Contract Manufacturing Industry in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth.

Asia Pacific is gaining attention among manufacturers for biologics production at reduced manufacturing cost. Emerging regions offering greater profit margins are major focus points for biopharmaceutical contract manufacturing, globally.”

Key Takeaways of Biopharmaceutical Contract Manufacturing Industry Study

• Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand.
• In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases.
• North America is anticipated to be the most lucrative region in the global Biopharmaceutical Contract Manufacturing Industry, offering growth opportunities to market players.
• The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029.

Revealing the key assumptions of the study. Insights from Experts.
https://www.futuremarketinsights.com/ask-question/rep-gb-2982

Key Market Players:

• Catalent Inc.
• Lonza Group Ag
• Patheon N.V. (Thermo Fisher Scientific Inc.)
• Abzena Plc.
• Sandoz International GmbH (Novartis AG)
• Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
• Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
• AbbVie Contract Manufacturing (AbbVie Inc.)
• Samsung Biologics Co. Ltd.
• ProBioGen AG
• Pfizer Centre Source Ltd (Pfizer Inc.)
• Novasep
• Biomeva GmbH
• Kbi Biopharma Inc
• Rentschler Biotechnologie GmbH
• Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)

Key Market Segments Covered in Biopharmaceutical Contract Manufacturing Industry Research:

By Platform Type:

• Mammalian Based
• Microbial Based

By Product Type:

• Monoclonal Antibodies
• Recombinant Protein
• Vaccine
• Insulin
• Growth factor
• Interferons
• Others

By Application Type:

• Clinical
• Commercial

By Therapeutic Area Type:

• Autoimmune Diseases
• Oncology
• Metabolic Diseases
• Ophthalmology
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Respiratory Disorders
• Others

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-2982

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube